Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TScan Therapeutics (TCRX) Assets Average (2021 - 2025)

Historic Assets Average for TScan Therapeutics (TCRX) over the last 5 years, with Q3 2025 value amounting to $280.4 million.

  • TScan Therapeutics' Assets Average fell 2242.53% to $280.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $280.4 million, marking a year-over-year decrease of 2242.53%. This contributed to the annual value of $321.6 million for FY2024, which is 3650.52% up from last year.
  • Latest data reveals that TScan Therapeutics reported Assets Average of $280.4 million as of Q3 2025, which was down 2242.53% from $315.6 million recorded in Q2 2025.
  • TScan Therapeutics' 5-year Assets Average high stood at $361.4 million for Q3 2024, and its period low was $158.9 million during Q3 2022.
  • Over the past 5 years, TScan Therapeutics' median Assets Average value was $256.5 million (recorded in 2024), while the average stood at $252.6 million.
  • As far as peak fluctuations go, TScan Therapeutics' Assets Average soared by 9136.88% in 2023, and later crashed by 2242.53% in 2025.
  • Quarter analysis of 5 years shows TScan Therapeutics' Assets Average stood at $196.5 million in 2021, then decreased by 7.24% to $182.3 million in 2022, then soared by 54.58% to $281.8 million in 2023, then increased by 27.61% to $359.6 million in 2024, then fell by 22.02% to $280.4 million in 2025.
  • Its Assets Average was $280.4 million in Q3 2025, compared to $315.6 million in Q2 2025 and $351.9 million in Q1 2025.